MRI-based assessment of residual disease after neoadjuvant chemotherapy in pregnant women with cervical cancer

Abstract\r\nPurpose\r\nThis study explores the performance of MRI in detecting residual disease after platinum-based neoadjuvant chemotherapy (NACT) in pregnant cervical cancer (CC) patients, which would serve as a surrogate of treatment response.\r\nMethods\r\nIn this retrospective single-centre study, consecutive pregnant cervical cancer patients treated with NACT and undergoing MRI examination before and at the end of the therapeutic protocol between 2010 and 2021 were included. Tumour maximum diameter and nodal status were evaluated in MRI at staging and after NACT. Patients exhibiting increased tumor burden post-NACT were excluded. On post-NACT the presence or absence of residual disease was recorded and the MRI diagnostic performance for assessing residual disease was calculated using histopathology at radical hysterectomy as the reference standard.\r\nResults\r\nThe study included 12 pregnant patients (median age 36 years, 27–42). At post-NACT MRI, residual disease was absent in 2/12 patients (16.7 %) while present in 10/12 (83.3 %). Histopathology was concordant in all patients without MRI residual disease and in 9/10 patients with MRI residual disease, while discordant in 1/10. MRI sensitivity, specificity, positive predictive value, negative predictive and accuracy for detecting residual disease were 100.0 % (95 %CI: 1.00, 1.00), 66.7 % (95 %CI: 0.13, 1.00), 90 % (95 %CI: 0.71, 1.00), 100 % (95 %CI: 1.00, 1.00), and 91.7 % (95 %CI: 0.76, 1.00) respectively (p = 0.045).\r\nConclusions\r\nThis study suggests that MRI has good diagnostic performance to detect residual disease after NACT in pregnant CC patients, and potentially assess response to treatment in this setting.